Skip to Content
Merck
CN
  • Synthesis and biological evaluation of some novel cyclic-imides as hypoglycaemic, anti-hyperlipidemic agents.

Synthesis and biological evaluation of some novel cyclic-imides as hypoglycaemic, anti-hyperlipidemic agents.

European journal of medicinal chemistry (2011-07-26)
Alaa A-M Abdel-Aziz, Adel S El-Azab, Sabry M Attia, Abdulrahman M Al-Obaid, Mohamed A Al-Omar, Hussein I El-Subbagh
ABSTRACT

Certain new halogenated cyclic-imides related to N-substituted phthalimide moiety were synthesized. Spacers of one or two carbon atom distances were inserted to connect the N-terminus of the cyclic-imide nuclei to the used heteroaryl groups to evaluate the effect of such alteration on biological activity. The synthesized compounds were subjected to hypoglycaemic and anti-hyperlipidemic evaluation. Some of the tested compounds proved to be more potent than the reference drugs glibenclamide and clofibrate. Compound 5e remarkably reduced serum glucose level by 55%; while 5c, 5e, 7d and 8e reduced total serum cholesterol by 58, 56, 54 and 53%, respectively. Those new cyclic-imides could be considered as useful template for future development to obtain more potent hypoglycaemic and anti-hyperlipidemic agents.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Glyburide, meets USP testing specifications
Sigma-Aldrich
Clofibrate, liquid